
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health is supported by a durable growth engine in Pharmacy Solutions, where 3Q26 revenue rose 25.8% to $3.732B and adj. EBITDA climbed 43.3% to $202M, while Pharmacy GP per script returned to growth and specialty/infusion revenue expanded about 34%. Its Provider Services business is also compounding, with revenue up 31% and organic growth around 16% excluding acquisitions, reflecting strong demand in home health, hospice, rehab, and home-based care. Management raised 2026 revenue and EBITDA guidance, expects 2027 EBITDA growth of 15%-20%, and has leverage of only about 1.8x alongside more than $700M of normalized annual OCF runway, giving it flexibility to fund LDD wins, AI, and M&A.
Bears say
BrightSpring Health is exposed to multiple fundamental weaknesses that support a negative outlook, including intense competition in both Pharmacy Solutions and Provider Services, where it must contend with local, regional, and national rivals while relying on continuous recruitment and retention of nurses, pharmacists, caregivers, therapists, and direct support professionals. Its business is also vulnerable to reimbursement pressure because a significant amount of revenue comes from Medicare and Medicaid, and adverse changes in rates, eligibility rules, or state-by-state payment methods could directly reduce profitability and cash flow. In addition, Pharmacy Solutions depends on drug utilization and supplier relationships, while software failures and financially stressed clients could disrupt operations, weaken demand, and impair customer relationships.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BrightSpring Health Services Inc (BTSG) Forecast
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares